Antibodies for cancer

Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy, Drug Development Research 61 172-187 (2004). 

Boyiadzis M, Foon KA Approved monoclonal antibodies for cancer therapies. Expert Opin Biol Ther 2008 8 1151. [PMID 18613766]... 

Baldwin, R.W. Byers, V.S. Monoclonal Antibodies for Cancer Detection an Therapy Academic Press London, 1985. 

In addition to the three main types of immunological products that are widely available, more specialized preparations include synthetic peptide immune response modifiers such as those used to block T-cell responses in multiple sclerosis labelled monoclonal antibodies for cancer therapy or diagnosis and hybrid toxins containing a bacterial or plant toxin subunit attached to an antibody or human cell receptor-binding protein, and also intended mainly for cancer therapy. These have rather limited applications and for the most part, are designed to suppress or exploit the specificity of immune responses rather than to stimulate them. 

S ouriau, C., Hudson, P.J., Recombinant antibodies for cancer diagnosis and therapy. Exp. Opin. Biol. Then 2003, 3(2), 305-318. 

Loisel S, Ohresser M, Pallardy M, Dayd e D, Berthou C, Cartron G, Watier H. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007 62 34-42. 

The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is primarily addressed to scientists working on recombinant antibodies as well as clinicians involved with antibody-based therapies. 

The biotechnology industry had its share of major R D and clinical trial success. The big gains for biotech products are mainly in anemia cancer TNF alpha inhibitors human insulin with short, mixed, and long duration of action interferon for multiple sclerosis and hepatitis C monoclonal antibodies for cancer RSV and immuno-inflammatory diseases. This success has resulted in attracting top pharmaceutical companies and R D funds for biosimilar products with improved properties. It is easier for start-up companies in the above areas to attract capital and angel investors or to conclude licensing deals and find marketing partners. 

Ferrara N, Hillan K J, Novotny W (2005). Bevaciznmab (Avastin), A hnmanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophy. Res. Commun. 333 328-335. 

Rituximab Clinical Development of the First Therapeutic Antibody for Cancer... 

Rituximab Clinical Development of the First Therapeutic Antibody for Cancer 219 Tab. 3 Key I DEC Pharmaceuticals staff in rituximab clinical trials... 

Many studies have been carried out using anti-carbohydrate antibodies for cancer diagnosis. These studies reveal a correlation between particular carbohydrate antigens and poor clinical prognosis, including metastasis (88,90-92). Therefore, specific carbohydrate structures expressed on the cancer cell surface may play a role in metastasis. The section below describes two hypotheses on carbohydrate-dependent cancer metastasis by selectin-dependent and selectin-independent mechanisms. 

Table 3 FDA-approved monoclonal antibodies for cancer treatment... 

Yang X-D et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Critical Reviews in Oncology Hematology 2001 38 17-23. 

Improving effector functions of antibodies for cancer treatment enhancing ADCC and CDC. Drug Des. 

Sakai, Y Shimada, K. Ooe, K. Yano, H. Endoscope containing immobilized antibody for cancer diagnosis. Jpn. Kokai Tokkyo Koho JP 06027110, 1994. 

Ward RL, Hawkins NJ, Smith GM. Unconjugated antibodies for cancer therapy lessons from the clinic. Cancer Treat Rev 1997 23 305-319. 

---